Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen dose response in ASD
NCT02278328Phase 1Completed
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of arbaclofen in Autism Spectrum Disorder (ASD) (3 arms). Primary endpoints: M50 Latency (Left Hemisphere), M50 Latency (Right Hemisphere) and 3 more. Started Feb 2016; status: completed.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02278328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278328.